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To the Editor:
     Invasive micropapillary carcinoma (IMPC) first was described in the breast (1).  The 
tumor cells are grouped in small cluster surrounded by a characteristic cleft (2). This type of 
cancer nearly always is associated with a poor prognosis and extensive lymph node 
metastases (3). IMPC of the ampullo-pancreatobiliary region has been reported only by 
Khayyata et al. (3), moreover, these tumors only rarely showed the clustered pattern 
exclusively. 
     We describe clinicopathologic and immunohistochemical features of a pure primary 
IMPC arising in the pancreatic head. Although we know of no previous report of effective 
adjuvant chemotherapy for IMPC, our patient's tumor responded completely to adjuvant 
chemotherapy with gemcitabine.
Case Report
     A 67-year-old man, presented with obstruction of the transverse colon to another 
hospital, where a colonic tumor was resected surgically with tumor-free margins. As 
intraoperative exploration also disclosed a small area of induration in the gall bladder, 
cholecystectomy was performed simultaneously. The colonic tumor was macroscopically a 
type 4 cancer, with no accompanying ulceration. Initial pathologic diagnoses were "poorly 
differentiated adenocarcinoma, so-called linitis plastica type", and "metastasis to the 
gallbladder". However, since the tumor of the colon differed in appearance from typical 
colon cancer, this lesion was consistent with the possibility of carcinoma metastasis from 
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another organ. Three months after the first surgical treatment the patient complainted of 
general malaise, and became jaundiced. A pancreatic head tumor was detected by computed 
tomography (CT), and he was referred to our institution for additional treatment.
     CT showed a nodular tumor in the head of the pancreas and multiple enlarged lymph 
nodes in the hepatoduodenal ligament. With administration of intravenous contrast material, 
enhancement of this tumor was poor in the early phase but relatively strong in the delayed 
phase ; the tumor margin was distinct. Magnetic resonance cholangiopancreatography 
(MRCP) showed expansion of the C-shaped duodenal loop around the pancreatic head. The 
lowermost common bile duct and main pancreatic duct were obstructed. Liver and lung 
metastases were not detected. Upper gastrointestinal endoscopy showed a elevated, eroded 
lesion surrounding the papilla of Vater, and a biopsy specimen from this lesion indicated 
adenocarcinoma. Initially, we diagnosed the pancreatic tumor as a recurrence of colon 
cancer representing mainly lymph node metastases, considering its expansile, nodular 
pattern of growth. As these findings argued against further surgical resection, we instead 
administered cisplatinum (CDDP) as a daily intravenous infusion from days 1 to 5 of 
chemotherapy, followed by cessation for two days. We continued this schedule for 1 month, 
but the outcome was progressive disease and signs of duodenal constriction appeared. 
     We decided upon palliative resection to reduce gastrointestinal symptoms. With the 
patient's informed consent we performed pancreatoduodenectomy, finding tumors in the 
remaining transverse and sigmoid colon in addition to the pancreatic tumor. We 
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simultaneously performed partial colectomy. The pancreatoduodenal reconstruction method 
was IIA. 
     Macroscopically, the tumor of the pancreas measured 45×55×35 mm, it had a soft 
consistency and was whitish to gray on cut section. The histologic pattern was characterized 
by small, round to ovoid micropapillary tumor cell clusters without fibrovascular cores, 
lying within clefts. In most areas the micropapillary clusters were closely packed, with 
scant intervening stroma. The cells had fairly abundent acidophilic cytoplasm, and showed 
moderate nuclear atypia (Fig. 1A). Focal lymphatic invasion was marked, and venous 
invasion was moderate. No area of typical adenocarcinoma was seen, with the tumor 
consisting purely of IMPC. Tumors of the colon and gallbladder showed the same findings 
limited to the submucosa, a pattern compatible with metastases from the pancreatic tumor.
     MUC 1 immunostaining was prominent and diffuse along the surfaces of cell clusters 
facing the stroma (Fig. 1B). Immunohistochemically, the tumor was positive for cytokeratin 
(CK) 7 (Fig. 1C) and negative for CK20 (Fig. 1D). Tumor cells were positive for 
carbohydrate antigen (CA) 19-9 (Fig. 1E) and negative for carcinoembryonic antigen 
(CEA) (Fig. 1F). 
     Adjuvant systemic chemotherapy with gemcitabine was begun on the 40th 
postoperative day as a biweekly intravenous infusion of gemcitabine 30 over min (900 
mg/m2), with outpatient administration 36 courses. We examined for recurrence by CT 
every 3 months. At 42 months after surgical resection the patient was well with no sign of 
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recurrence when he died suddenly of accidental trauma. No neoplastic lesions were detected 
in other organs such as breast, lung, or urinary tract throughout the course.
Discussion
     We report a unique case of a patient with a pure invasive micropapillary pancreatic 
carcinoma. After he received gemcitabine as adjuvant chemotherapy following 
pancreatoduodenectomy, he survived disease-free for more than 3 years.
     Invasive micropapillary carcinomas have been associated with a high degree of 
aggressiveness, arising in various organs including breast, urinary bladder, lung, and colon, 
manifested by advanced stage at presentation, massive lymph node metastasis, and 
extensive lymphatic and vascular invasion. Ampullo-pancreatobiliary invasive 
micropapillary carcinomas have been reported to account for 4.1% of the carcinomas in this 
region (3). Extent of the micropapillary component in primary tumors has been classified 
by Khayyata et al. (3) as focal (20% to 50% of the tumor), predominant (51 to 80%), or 
diffuse (over 80%). Finding the diffuse type to be very rare, those authors reported only two 
such cases originating from the pancreas and two others originating from the periampullary 
region. Our case, a pure IMPC without areas of typical adenocarcinoma of the pancreas, 
needed to be distinguished from an IMPC that had metastasized to this region from another 
organ; invasive micropapillary carcinoma can be pure in metastases even when this pattern 
is only focally present in the primary tumor. Moreover, the IMPC morphology is not 
specific for any anatomic location. 
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In cases with periampullary origin, liver injury from biliary tract obstruction should be 
evident even at an early stage. In our case, liver injury was not apparent with a tumor mass 
in the pancreatic head could be demonstrated by CT. 
     In addition to clinical information, immunohistochemical stains such as CK7 and 
CK20 can be helpful in identifying the primary tumor site, since the CK7/CK20 
immunohistochemical staining pattern usually is retained in both the primary IMPC and 
metastatic foci (2,4). IMPC of the breast, lung, and parotid gland all are CK7+/CK20-, as is 
micropapillary transitional cell carcinoma. IMPCs of the colon, however, are 
CK7-/CK20+ ―  as are typical colonic cancers. In our case the pancreatic tumor and the 
presumable metastatic tumors in the colon and gallbladder all were CK7+/CK20-. In 
addition, the tumors of colon and gallbladder had the same morphology as the pancreatic 
lesion as well as a distribution limited to the submucosa. These findings indicated that the 
colon and gallbladder tumors had metastasized from the pancreatic tumor.
     MUC 1, a glycoprotein normally located at the apical cell surface of normal glandular 
epithelium, has an important physiologic role in maintenance of lumina and an inhibitory 
role in tumor cell-stroma interaction. In in vitro studies, increasing MUC 1 expression was 
associated with decreased adhesion between adjacent cells and between cells and the 
extracellular matrix (5). In typical carcinomas of the pancreas increased expression of MUC 
1 was associated with low-grade cytologic features and good prognosis, while aberrant 
expression such as intracytoplasmic localization was associated with poor outcome 
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independently of tumor differentiation (6).  In our case expression of MUC 1 in neoplastic 
cell clusters was present in the surface facing the stroma, as a narrow band of staining; 
significant lymphotropism was observed. IMPC, then, shows reversal of cellular polarity in 
an "inside-out" growth pattern where the surfaces of tumor cells that face the stroma acquire 
apical secretory properties. This has been demonstrated in earlier studies by electron 
microscopy (7) as well as immunohistochemical staining for MUC 1 (8). MUC 1, then may 
be an important factor in detachment of cells from the stroma, contributing to a 
micropapillary morphology as well as facilitating spread of cells by dissection of the 
stroma.
     Gemcitabine (difluorodeoxycytidine) is a nucleoside analogue that is highly effective 
against typical pancreatic cancer (9). Gemcitabine was effective even in our IPMC case. 
Since this tumor originated from the pancreas, it may have retained some properties of 
typical pancreatic carcinoma, as verified by the CK7/CK20 immunohistochemical staining 
pattern. Characteristics of this tumor shared in common with typical pancreatic carcinoma 
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Figure 1. Pathological examination. A、The histologic pattern of the pancreatic tumor. 
Hematoxylin and eosin, x200. B、Immunohistochemical analysis for MUC 1. Original 
magnification, x100. C、Immunohistochemical analysis for CK7. Original magnification, 
x100. D、Immunohistochemical analysis for CK20. Original magnification, x100. E、
Immunohistochemical analysis for CA19-9. Original magnification, x100. 
Immunohistochemical analysis for CEA. Original magnification, x100.
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